218 related articles for article (PubMed ID: 31186081)
21. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2.
Dutta M; Das B; Mohapatra D; Behera P; Senapati S; Roychowdhury A
Life Sci; 2022 Jul; 301():120592. PubMed ID: 35504332
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between SUV of (18)F-FDG PET-CT and the expression of GLUT1, MVD and Ki67 in non-small cell lung cancer].
Duan Y; Yu LJ; Lu PO; Wang WZ
Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):764-7. PubMed ID: 19173807
[TBL] [Abstract][Full Text] [Related]
24. Silence of ATAD2 inhibits proliferation of colorectal carcinoma via the Rb-E2F1 signaling.
Wang JH; Yu TT; Li Y; Hao YP; Han L; Xu KY; Xu P
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):6055-6063. PubMed ID: 32572920
[TBL] [Abstract][Full Text] [Related]
25. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
[TBL] [Abstract][Full Text] [Related]
26. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
27. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
28. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.
Mamede M; Higashi T; Kitaichi M; Ishizu K; Ishimori T; Nakamoto Y; Yanagihara K; Li M; Tanaka F; Wada H; Manabe T; Saga T
Neoplasia; 2005 Apr; 7(4):369-79. PubMed ID: 15967114
[TBL] [Abstract][Full Text] [Related]
29. Emerging oncogene ATAD2: Signaling cascades and therapeutic initiatives.
Nayak A; Dutta M; Roychowdhury A
Life Sci; 2021 Jul; 276():119322. PubMed ID: 33711386
[TBL] [Abstract][Full Text] [Related]
30. Decreasing Arl4c expression by inhibition of AKT signal in human lung adenocarcinoma cells.
Sun Y; Zhang Z; Xiang F; Zhang M; Chen Q; Tang L; Zhu L; Liu J; Meng Z; Hu J; Luo X; Ni Z; Wang X
Life Sci; 2020 Apr; 246():117428. PubMed ID: 32057901
[TBL] [Abstract][Full Text] [Related]
31. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
Cai W; Ni W; Jin Y; Li Y
Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of microRNA-186 inhibits angiogenesis in retinoblastoma via the Hedgehog signaling pathway by targeting ATAD2.
Wu S; Han M; Zhang C
J Cell Physiol; 2019 Aug; 234(10):19059-19072. PubMed ID: 30993715
[TBL] [Abstract][Full Text] [Related]
33. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
[TBL] [Abstract][Full Text] [Related]
34. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
35. Fructose 1,6-Bisphosphatase 1 Expression Reduces
Chen R; Zhou X; Huang G; Liu J
Contrast Media Mol Imaging; 2019; 2019():9463926. PubMed ID: 30723389
[TBL] [Abstract][Full Text] [Related]
36. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
37. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
Fleming IN; Andriu A; Smith TA
Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
[TBL] [Abstract][Full Text] [Related]
38. ATAD2 silencing decreases VEGFA secretion through targeting has-miR-520a to inhibit angiogenesis in colorectal cancer.
Hong S; Chen S; Wang X; Sun D; Yan Z; Tai J; Bi M
Biochem Cell Biol; 2018 Dec; 96(6):761-768. PubMed ID: 29958090
[TBL] [Abstract][Full Text] [Related]
39. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
40. CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro.
Luo J; Chimge NO; Zhou B; Flodby P; Castaldi A; Firth AL; Liu Y; Wang H; Yang C; Marconett CN; Crandall ED; Offringa IA; Frenkel B; Borok Z
Int J Cancer; 2018 Dec; 143(12):3169-3180. PubMed ID: 30325015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
